Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders

Changes of voltage-gated ion channels and ligand-gated receptor channels caused by mutation or autoimmune attack are the cause of so-called channelopathies in the central and peripheral nervous system. We present the pathophysiology of channelopathies of the neuromuscular junction in terms of loss-of-function and gain-of-function principles. Autoantibodies generally have reduced access to the central nervous system, but in some cases this is enough to cause disease. A review is provided of recent findings implicating autoantibodies against ligand-activated receptor channels and potassium channels in psychiatric and neurological disorders, including schizophrenia and limbic encephalitis. The emergence of channelopathy-related neuropsychiatric disorders has implications for research and practice.

[1]  D. Manahan‐Vaughan,et al.  Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis , 2013, Neuropharmacology.

[2]  M. Daly,et al.  Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis , 2013, The Lancet.

[3]  M. Skalej,et al.  Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. , 2013, JAMA psychiatry.

[4]  J. Dalmau,et al.  Paraneoplastic neurological syndromes. , 1988, Cancer Investigation.

[5]  K. Berman,et al.  Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. , 2012, The American journal of psychiatry.

[6]  N. Fineberg,et al.  Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. , 2012, The British journal of psychiatry : the journal of mental science.

[7]  J. Verschuuren,et al.  Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. , 2012, Brain : a journal of neurology.

[8]  I. Rosenzweig,et al.  Abnormalities in thalamic neurophysiology in schizophrenia: Could psychosis be a result of potassium channel dysfunction? , 2012, Neuroscience & Biobehavioral Reviews.

[9]  S. J. James,et al.  Cerebral folate receptor autoantibodies in autism spectrum disorder , 2012, Molecular Psychiatry.

[10]  B. Crespi,et al.  Comparative immunogenetics of autism and schizophrenia , 2011, Genes, brain, and behavior.

[11]  C A Jones,et al.  Animal models of schizophrenia , 2011, British journal of pharmacology.

[12]  Christian G Bien,et al.  Autoantibodies associated with diseases of the CNS: new developments and future challenges , 2011, The Lancet Neurology.

[13]  Jim van Os,et al.  Late onset autism and anti-NMDA-receptor encephalitis , 2011, The Lancet.

[14]  J. Schott,et al.  Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis , 2011, Annals of neurology.

[15]  L. Crepaldi,et al.  Altered levels of glutamatergic receptors and Na+/K+ ATPase-α1 in the prefrontal cortex of subjects with schizophrenia , 2011, Schizophrenia Research.

[16]  R. Balice-Gordon,et al.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.

[17]  U. Hegerl,et al.  Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings , 2011, Psychopharmacology.

[18]  Jim van Os,et al.  The environment and schizophrenia , 2010, Nature.

[19]  Peter B. Jones,et al.  Disease-relevant autoantibodies in first episode schizophrenia , 2010, Journal of Neurology.

[20]  L. Ptáček,et al.  Episodic Neurological Channelopathies , 2010, Neuron.

[21]  R. Balice-Gordon,et al.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series , 2010, The Lancet Neurology.

[22]  A. Gomez,et al.  Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction , 2010, Autoimmunity.

[23]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[24]  S. Cannon Voltage‐sensor mutations in channelopathies of skeletal muscle , 2010, The Journal of physiology.

[25]  D. Kullmann,et al.  Neurological channelopathies: new insights into disease mechanisms and ion channel function , 2010, The Journal of physiology.

[26]  M. Hanna,et al.  Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? , 2010, The Journal of physiology.

[27]  A. Vincent,et al.  Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems , 2010, Journal of Clinical Immunology.

[28]  J. Dalmau,et al.  Antibodies and neuronal autoimmune disorders of the CNS , 2010, Journal of Neurology.

[29]  F. Lehmann-Horn,et al.  Sodium channelopathies of skeletal muscle result from gain or loss of function , 2010, Pflügers Archiv - European Journal of Physiology.

[30]  M. Mühlethaler,et al.  Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. , 2010, The Journal of clinical investigation.

[31]  L. Ptáček,et al.  Mutations in Potassium Channel Kir2.6 Cause Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis , 2010, Cell.

[32]  Glinda S Cooper,et al.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. , 2009, Journal of autoimmunity.

[33]  A. Vincent,et al.  The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. , 2009, The American journal of pathology.

[34]  P. Striano,et al.  Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients , 2009, Journal of Neuroimmunology.

[35]  D. Bonifati,et al.  AChR deficiency due to ε-subunit mutations: two common mutations in the Netherlands , 2009, Journal of Neurology.

[36]  B. Volpe,et al.  Losing your nerves? Maybe it's the antibodies , 2009, Nature Reviews Immunology.

[37]  A. Vincent,et al.  Autoimmune disorders of the neuromuscular junction. , 2008, Neurology India.

[38]  Michelle J Chandley,et al.  Increased antibodies for the α7 subunit of the nicotinic receptor in schizophrenia , 2009, Schizophrenia Research.

[39]  Michael K. Hutchinson,et al.  PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY , 2008, Neurology.

[40]  David G. Amaral,et al.  Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism , 2008, Brain, Behavior, and Immunity.

[41]  O. Gervásio,et al.  Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction , 2008, Annals of neurology.

[42]  N. Blau,et al.  Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. , 2007, Neuropediatrics.

[43]  B. Fontaine,et al.  Hypokalemic periodic paralysis: A model for a clinical and research approach to a rare disorder , 2007, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.

[44]  J. Chapman,et al.  Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. , 2007, Arthritis and rheumatism.

[45]  B. Volpe,et al.  Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[46]  Karl J. Friston,et al.  Synaptic Plasticity and Dysconnection in Schizophrenia , 2006, Biological Psychiatry.

[47]  T. Yoshio,et al.  Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[48]  A. Vincent,et al.  Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis , 2005, Current opinion in neurology.

[49]  Nenad Blau,et al.  Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. , 2005, The New England journal of medicine.

[50]  R. Jonsson,et al.  Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors , 2005, European journal of neurology.

[51]  Masahiko Watanabe,et al.  NR2 to NR3B subunit switchover of NMDA receptors in early postnatal motoneurons , 2005, The European journal of neuroscience.

[52]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[53]  F. Lehmann-Horn,et al.  Electrophysiology and molecular pharmacology of muscle channelopathies. , 2004, Revue neurologique.

[54]  R. Gómez,et al.  Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera , 2004, Glia.

[55]  A. Vincent,et al.  Antibodies in Myasthenia Gravis and Related Disorders , 2003, Annals of the New York Academy of Sciences.

[56]  L. Phillips The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.

[57]  A. Blamire,et al.  Maternal neuronal antibodies associated with autism and a language disorder , 2003, Annals of neurology.

[58]  H. Johansen-Berg,et al.  Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy , 2002, Journal of Neuroimmunology.

[59]  M. Pusch Myotonia caused by mutations in the muscle chloride channel gene CLCN1 , 2002, Human mutation.

[60]  R. Gómez,et al.  Antibodies Against Cerebral M1 Cholinergic Muscarinic Receptor from Schizophrenic Patients: Molecular Interaction1 , 2002, The Journal of Immunology.

[61]  B. Diamond,et al.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus , 2001, Nature Medicine.

[62]  K. Ohno,et al.  Congenital myasthenic syndromes: recent advances. , 1999, Archives of neurology.

[63]  F. Lehmann-Horn,et al.  Voltage-gated ion channels and hereditary disease. , 1999, Physiological reviews.

[64]  J. Wokke,et al.  Acquired slow–channel syndrome: A form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel , 1998, Annals of neurology.

[65]  A. Vincent,et al.  Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. , 1996, The Journal of clinical investigation.

[66]  K. Ohno,et al.  New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. , 1996, Human molecular genetics.

[67]  J. G. van Dijk,et al.  Acquired neuromyotonia: Evidence for autoantibodies directed against K+ channels of peripheral nerves , 1995, Annals of neurology.

[68]  G. L. Curran,et al.  Macromolecular permeability across the blood nerve and blood brain barriers Joseph F. Poduslo, Geoffry L. Curran, Carole T. Berg. Molecular Neurobiology Laboratory, Mayo Foundation, Rochester, MN 55905 USA , 1994, Neurobiology of Aging.

[69]  B. Sakmann,et al.  Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.

[70]  V. Singh,et al.  Detection of maternal antibodies in infantile autism. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.

[71]  C. Hulsebosch,et al.  Time course of penetration of xenogeneic IgG into the central nervous system of the neonatal rat: an immunohistochemical and radionuclide tracer study , 1989, Journal of Neuroimmunology.

[72]  P. De Camilli,et al.  Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. , 1988, The New England journal of medicine.

[73]  A. Vincent,et al.  The slow channel syndrome. Two new cases. , 1987, Brain : a journal of neurology.

[74]  A. Engel,et al.  Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Hammerstad,et al.  The origin and turnover rates of cerebrospinal fluid albumin and gamma-globulin in man. , 1970, Journal of the neurological sciences.

[76]  H. Lerche,et al.  Hereditary channelopathies in neurology. , 2010, Advances in experimental medicine and biology.

[77]  J. Stockman Autoantibodies to Folate Receptors in the Cerebral Folate Deficiency Syndrome , 2007 .

[78]  J. Newsom-Davis,et al.  Immunopathology of the Lambert-Eaton myasthenic syndrome , 2004, Springer Seminars in Immunopathology.

[79]  T. Shike,et al.  Animal models. , 2001, Contributions to nephrology.

[80]  B. Rabin,et al.  Autoimmunity in schizophrenia: a review of recent findings. , 1993, Annals of medicine.

[81]  The Environment and , 1992 .

[82]  W D Rowe,et al.  Identification of risk. , 1986, Progress in clinical and biological research.

[83]  Rowe Wd,et al.  Identification of risk. , 1986 .